Company Overview

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on the development and commercialization of innovative treatments for severe allergic reactions, including anaphylaxis. The company operates within the biopharmaceutical and specialty therapeutics industries, with a primary emphasis on emergency allergy care. Its core product is neffy®, an epinephrine nasal spray designed as a needle-free alternative to traditional epinephrine auto-injectors, which represents the company’s primary revenue driver following regulatory approvals.

The company targets patients at risk of anaphylaxis, caregivers, healthcare providers, schools, and other public or institutional settings where rapid treatment of allergic reactions is critical. ARS Pharmaceuticals positions itself strategically by addressing well-documented limitations of injectable epinephrine, such as needle aversion and administration complexity. Founded in 2015, the company evolved from a clinical-stage biotechnology firm into a commercial-stage pharmaceutical company following successful clinical trials and regulatory milestones, including U.S. FDA approval of neffy®.

Business Operations

ARS Pharmaceuticals operates primarily as a single-segment biopharmaceutical company, generating value through the development, regulatory approval, and commercialization of neffy®. The company does not report multiple operating segments, and its business model centers on intellectual property, clinical development expertise, and commercial partnerships. Manufacturing is conducted through third-party contract manufacturers, while commercialization is supported by internal sales and marketing capabilities in key markets.

Operations are concentrated in the United States, with expanding international activities through regulatory filings and strategic partners. The company controls proprietary drug-device combination technology enabling intranasal epinephrine delivery. ARS Pharmaceuticals has established commercial and distribution partnerships in select international markets, particularly in Europe, to support regulatory approval and future commercialization outside the U.S.

Strategic Position & Investments

The company’s strategic direction is focused on establishing neffy® as a new standard of care for the treatment of anaphylaxis and expanding its market penetration across pediatric and adult patient populations. Growth initiatives include lifecycle management of neffy®, label expansions, and geographic expansion into international markets following regulatory approvals.

ARS Pharmaceuticals has invested heavily in clinical development, regulatory compliance, and commercial infrastructure rather than pursuing broad diversification through acquisitions. Its pipeline is centered on epinephrine-based intranasal formulations, reflecting a strategy of depth over breadth. Public disclosures indicate no material acquisitions of other pharmaceutical companies, with capital primarily allocated toward product launch execution, post-marketing commitments, and global regulatory efforts.

Geographic Footprint

ARS Pharmaceuticals is headquartered in the United States, with its principal executive offices located in California. The company’s primary commercial focus is the U.S. market, where neffy® has received regulatory approval and is being launched commercially.

Internationally, the company has established a presence through regulatory submissions and partnerships in Europe, including interactions with the European Medicines Agency. While it does not maintain extensive physical operations across multiple continents, ARS Pharmaceuticals exerts international influence through licensing, distribution agreements, and global intellectual property protections designed to support future market expansion.

Leadership & Governance

ARS Pharmaceuticals was co-founded by Richard Lowenthal, who continues to play a central role in shaping the company’s long-term strategy and operational execution. Leadership emphasizes patient-centric innovation, regulatory rigor, and disciplined capital allocation as the company transitions from development-stage to commercial operations.

Key members of the executive leadership team include:

• Richard Lowenthal – President and Chief Executive Officer
• Eric Karas – Chief Financial Officer
• Sherry Martin – Chief Commercial Officer
• Julie McHugh – Chief Operating Officer

The governance structure includes an independent board of directors with experience across biotechnology, pharmaceuticals, and commercialization, supporting oversight, risk management, and strategic guidance aligned with shareholder and patient interests.